Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,001 public trials 2,038 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, not recruiting

Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL

NCT04938232

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin Lymphoma, +9 more
Locations
  • University of Chicago Medicine Chicago, Illinois, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Brigham and Women's Hospital Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Active, not recruiting

Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia

NCT04624906

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Tom Baker Cancer Centre Calgary, Alberta, Canada
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • Vancouver General Hospital Vancouver, British Columbia, Canada
  • QEII Health Sciences Centre Halifax, Nova Scotia, Canada
View Trial Details
Active, not recruiting

A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)

NCT05460533

Conditions
B-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, DNA Virus Infections, +19 more
Locations
  • Children's Hospital of Los Angeles (Data Collection Only) Los Angeles, California, United States
  • Stanford University (Data Collection Only) Stanford, California, United States
  • Children's Hospital Colorado (Data Collection Only) Aurora, Colorado, United States
  • Johns Hopkins University (Data Collection Only) Baltimore, Maryland, United States
View Trial Details
Active, not recruiting

Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

NCT03617731

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Uniklinik RWTH Aachen, Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation Aachen, Germany
  • Helios Klinikum Bad Saarow, Klinik für Hämatologie, Onkologie und Palliativmedizin Bad Saarow, Germany
  • Charité, Campus Benjamin Franklin , III. Medizinische Abteilung (Hämatologie/Onkologie) Berlin, Germany
  • Vivantes Klinikum Neukölln, Klinik für Hämatologie und Onkologie Berlin, Germany
View all 72 locations
View Trial Details
Active, not recruiting

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

NCT04323956

Conditions
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, +22 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Mayo Clinic in Rochester Rochester, Minnesota, United States
View Trial Details

Related conditions